Government of Italy   Report issue

Government Phase 1 Phase 2 Phase 3 Phase 4
Founded: Rome Italy (1946)

Organization Overview

First Clinical Trial
2001
NCT01060605
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

ASST Fatebenefratelli Sacco | Azienda Ospedaliera Fatebenefratelli e Oftalmico | Giuliano Rizzardini | Local Health Authority of Modena | Ministero della Salute, Italy | Ministero dell'Università e della Ricerca, Italia | Ministry of Education, Universities and Research, Italy | Ministry of Health, Italy | Public Health Service of South Tyrol, Italy

Active Ingredients

Drugs in Phase 4 Trials (17)

autologous microbiome (1 trial)

carbamazepine (tegretol) (1 trial)

cobicistat (stribild) (1 trial)

darunavir (prezista) (1 trial)

dolutegravir (tivicay) (2 trials)

emtricitabine (emtriva) (1 trial)

gabapentin (neurontin) (1 trial)

hypromelloses (1 trial)

lamotrigine (lamictal) (1 trial)

levetiracetam (keppra) (1 trial)

oxcarbazepine (trileptal) (1 trial)

ozonated oil (1 trial)

tenofovir (viread) (1 trial)

tenofovir alafenamide (genvoya) (1 trial)

topiramate (topamax) (1 trial)

valproic acid (depakene) (1 trial)

zonisamide (Zonegran) (1 trial)

Drugs in Phase 3 Trials (22)

alendronic acid (fosamax) (1 trial)

baricitinib (olumiant) (1 trial)

calcium (1 trial)

cefixime (suprax) (1 trial)

clavulanate (Augmentin) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

dexamethasone (1 trial)

doxorubicin (Doxil) (1 trial)

enoxaparin (lovenox) (1 trial)

favipiravir (1 trial)

fibrinogen (human) (RiaSTAP) (1 trial)

genistein (3 trials)

lamivudine (epivir) (1 trial)

methylprednisolone (medrol) (1 trial)

nitrofurantoin (furadantin) (1 trial)

pneumococcal 13-valent conjugate vaccine (prevnar 13) (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

remdesivir (Veklury) (1 trial)

resveratrol (1 trial)

sirolimus (rapamune) (1 trial)

trimethoprim (1 trial)

vitamin d3 (1 trial)

Drugs in Phase 2 Trials (5)

acetylcysteine (mucomyst) (1 trial)

allogeneic bone marrow (1 trial)

allogeneic pancreatic islet cells (1 trial)

ivabradine (corlanor) (1 trial)

lorazepam (ativan) (1 trial)

Drugs in Phase 1 Trials (3)

fentanyl (Innovar) (1 trial)

sarilumab (kevzara) (1 trial)

sucrose (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arrhythmias, Cardiac (Phase 2)

Autism Spectrum Disorder (Phase 4)

Autistic Disorder (Phase 4)

Bone Diseases (Phase 3)

Cardiomyopathies (Phase 2)

Cardiomyopathy, Dilated (Phase 2)

Cataract (Phase 4)

Communicable Diseases (Phase 4)

Congenital Abnormalities (Phase 3)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 1 (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Epilepsies, Partial (Phase 4)

Epilepsy (Phase 4)

Eye Infections (Phase 4)

Heart Failure (Phase 2)

HIV Infections (Phase 4)

Infections (Phase 4)

Inflammation (Phase 3)

Insulin Resistance (Phase 3)

Kidney Diseases (Phase 3)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Metabolic Syndrome (Phase 3)

Myelodysplastic Syndromes (Phase 2)

Osteoporosis (Phase 3)

Pneumococcal Infections (Phase 3)

Pneumonia (Phase 3)

Preleukemia (Phase 2)

Renal Insufficiency, Chronic (Phase 3)

Respiratory Distress Syndrome (Phase 1)

Respiratory Distress Syndrome, Newborn (Phase 1)

Sarcoma (Phase 3)

Syndrome (Phase 3)

Thrombosis (Phase 3)

Vesico-Ureteral Reflux (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 25
  • # of Trial APIs: 47